Skip to main content

Autoimmune Disorder Drug Delivery Devices Market to Witness Huge Growth by 2020-2030

Healthcare experts have found the autoimmune disorders industry to be one of the most rapidly evolving markets. The global market for autoimmune disorder drug delivery devices is predicted to grow at a CAGR of 15.25% over the forecast period of 2020-2030. The market is driven by certain factors, including the increasing global geriatric population, increasing incidence of chronic diseases including autoimmune disorders, and rise in demand for self-injectable systems.

The market is favored by the development of autoimmune disorder drug delivery devices for several clinical areas such as systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, multiple sclerosis, and psoriasis. The increase in the geriatric population and incurable autoimmune disorders across the globe are expected to translate into a significantly higher demand for autoimmune disorder drug delivery devices.

Furthermore, the companies are investing huge amounts in research and development of autoimmune disorder drug delivery devices. The clinical trial landscape of different autoimmune disorders has been on the rise in recent years, and this will drive the autoimmune disorder drug delivery devices market in the future.

Within the research report, the market is segmented based on indication, product type, manufacturing type, and region. Each of these segments covers the market’s snapshot over the projected years, the inclination of the market revenue, underlying patterns, and trends by using analytics on the primary and secondary data obtained

View Report - https://bisresearch.com/industry-report/autoimmune-disorder-drug-delivery-devices-market.html

 Market Segmentation

•    Indication – Systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, multiple sclerosis, and psoriasis

•    Product Type – Pen injectors, auto-injectors, pre-filled syringes, and vials

•    Manufacturing Type – In-house manufacturing and outsourced manufacturing


Regional Segmentation

•    North America – U.S., Canada

•    Europe – Germany, France, Italy, U.K., Spain, Russia, and Rest-of-Europe

•    Asia-Pacific – China, Japan, India, Taiwan, South Korea, Singapore, Australia, and Rest-of-Asia-Pacific (RoAPAC)

•    Latin America – Brazil, Mexico, and Rest-of-the-Latin America

•    Rest-of-the-World


Growth Drivers

•    Increased Prevalence of Autoimmune Disorders

•    Technological Advancements in the Field of Pre-Filled Syringes

•    Rising Geriatric Population

•    Surge of Biosimilars and Biologics in the Pharmaceutical Market

•    Device Connectivity to Ease Competitive Pressure


Market Challenges

•    Strict Legal Requirements and Regulations

•    Alternative Drug Delivery Technology


Market Opportunities

•    Providing Injectable Drug Delivery Devices for Untapped Autoimmune Disorders

•    Opportunities of Personalizing Treatments in Autoimmune Diseases


Key Companies Profiled

AbbVie Inc., Amgen Inc., F. Hoffmann- La Roche Ltd., Novartis AG, GlaxoSmithKline Plc, Bristol Myers Squibb Company, Biogen Inc., Merck KGaA, Bayer AG, Johnson & Johnson Services Inc., Teva Pharmaceutical Industries Ltd., Eli Lily and Company, Sanofi S.A., UCB Inc., and Takeda Pharmaceutical Company Limited, among others.

Request a Sample- https://bisresearch.com/requestsample?id=1010&type=download

Labels:

Comments

Post a Comment

Popular posts from this blog

Microbiome Therapeutics Market Growth, Segmentation, Opportunity and Forecast to 2032

  Global microbiome therapeutics market is expected to grow further in the coming years due to the continuous increase in awareness and need for better and safer treatment alternatives and the dominance of gastrointestinal (GI) and infectious diseases segment can be attributed to the existing dominance of microbiome therapeutics available for a variety of indications ranging from diarrhea and gut dysbiosis to skin disorders, cancer indications among others. The global microbiome therapeutics market which accounted for $306.3 million in 2021 is expected to reach $3,204 million by 2032, reporting a CAGR of 24.95% during the forecast period 2022-2032. The existing   microbiome therapeutics market    is favored by multiple factors, including the rising geriatric populations coupled with the increasing adoption of inorganic growth strategies by key players in the market. Impact of COVID-19 There were numerous consequences due to the COVID-19 pandemic, especially...
Post a Comment
Read more

Ligase Market Opportunities, Strategies, Share, Segmentation, In-depth Analysis 2032

  The global ligase market is progressing rapidly with a significant increase in the research and development activities pertaining to a wide range of ligase product for disease detection, accentuating their criticality in healthcare. Ligase enzyme has a critical role in the molecular diagnostics approach, as it ensures the safe and effective application of targeted therapeutics. Most of the players in the global ligase market offer products encompassing the ligation kits and enzymes. The global  ligase market  is projected to reach $651.4 million by 2032 from $371.2 million in 2021, at a CAGR of 5.29% during the forecast period 2022-2032. The growth in the global ligase market is expected to be driven by factors such as the increasing prevalence of infectious and genetic diseases on a global level, rising awareness of enzyme based diagnostic testing and significant number of funding for executing research and development.   Impact Several techniques are employed in ...
Post a Comment
Read more

PD-1/PDL-1 Inhibitor Market Growth Prospects, Emerging Trends and Forecast to 2032

  PD-1/PDL-1 inhibitors are immune-therapeutic agents used in the treatment of various cancer indications, mostly in the advanced stages. PD-1/PDL-1 inhibitors are monoclonal antibodies majorly of IgG1 and IgG4 types to be administered to patients via injection The current market already has seven approved products in the U.S. and a large number of research activities are currently undergoing in this segment generating interest of commercial as well as academic research institutions. In the current period of precision medicine and providing targeted treatment, identification of target patient has become very important as well as complicated. With the emergence of diagnostic test identifying predictive biomarkers, the selection and administration of targeted treatment has become comparativlely conveninent and efficient. PD-1/PDL-1 inhibitors market   are majorly indicated for the treatment of advanced cases of different cancer indications. The PD-1/PDL-1 inibitor treatment has ...
Post a Comment
Read more